Pediatrix Medical Group reported second quarter 2026 results with net revenue of $488 million, up 4.0% year-over-year, driven by acquisition growth and improved reimbursement metrics despite a 2.1% decline in same-unit patient volume. The company generated net income of $40 million, or $0.49 per diluted share, compared to $39 million ($0.46) in the prior year period. Adjusted EBITDA reached $76 million, up from $73 million, while adjusted EPS was $0.63 versus $0.53 previously. For the six-month period, net income totaled $69 million ($0.85 per share) on revenue of $964 million. Management reaffirmed its full-year 2026 Adjusted EBITDA guidance of $280 million to $300 million and utilized $42.7 million for share repurchases during the quarter. Pediatrix Medical Group operates in the healthcare industry, providing physician services including neonatology, obstetrics, and pediatric subspecialties.

Pediatrix Medical Group, Inc. announced the separation of Mary Ann E. Moore, Vice President, General Counsel, and Chief Administrative Officer, effective October 31, 2010, as a termination without cause. The company appointed David Haddock as the new Executive Vice President, General Counsel, and Secretary. Pediatrix Medical Group, Inc. operates in the healthcare industry and provides medical services to pediatric patients.